PharmaEngine, Inc. (TPEX:4162)

Taiwan · Delayed Price · Currency is TWD

64.30

-1.50 (-2.28%)

Jul 28, 2026, 1:30 PM CST

-17.35% (1Y)

Market Cap	9.45B -15.4%
Revenue (ttm)	963.83M -62.1%
Net Income	422.55M -76.1%
EPS	2.93 -76.2%
Shares Out	143.68M
PE Ratio	22.46
Forward PE	n/a
Dividend	2.00 (3.03%)
Ex-Dividend Date	Aug 13, 2025

Volume	593,776
Open	65.80
Previous Close	65.80
Day's Range	63.90 - 66.50
52-Week Range	53.00 - 81.50
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 45

Stock Exchange Taipei Exchange

Ticker Symbol 4162

Full Company Profile

Financial Performance

In 2025, PharmaEngine's revenue was 911.42 million, a decrease of -63.88% compared to the previous year's 2.52 billion. Earnings were 387.64 million, a decrease of -77.86%.

Financial Statements